All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 Gender, female Gender, male metastasis (visceral) PDL1 < 25% PDL1 >25%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mUC - M - all population, anti-PD-(L)1 vs. non active control, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results JAVELIN Bladder 100 (all population), 2020 0.69 [0.56; 0.86]
0.69 [0.56 ; 0.86 ] JAVELIN Bladder 100 (all population), 2020 1 0% 700 NA not evaluable deaths (OS) (extension)detailed results JAVELIN Bladder 100 (all population), 2020 0.76 [0.63; 0.92]
0.76 [0.63 ; 0.92 ] JAVELIN Bladder 100 (all population), 2020 1 0% 700 NA not evaluable PFS (extension)detailed results JAVELIN Bladder 100 (all population), 2020 0.54 [0.45; 0.64]
0.54 [0.45 ; 0.64 ] JAVELIN Bladder 100 (all population), 2020 1 0% 700 NA not evaluable progression or deaths (PFS)detailed results JAVELIN Bladder 100 (all population), 2020 0.62 [0.52; 0.74]
0.62 [0.52 ; 0.74 ] JAVELIN Bladder 100 (all population), 2020 1 0% 700 NA not evaluable DCRdetailed results JAVELIN Bladder 100 (all population), 2020 1.85 [1.35; 2.54]
1.85 [1.35 ; 2.54 ] JAVELIN Bladder 100 (all population), 2020 1 0% 700 NA not evaluable objective responses (ORR)detailed results JAVELIN Bladder 100 (all population), 2020 7.46 [2.53; 21.97]
7.46 [2.53 ; 21.97 ] JAVELIN Bladder 100 (all population), 2020 1 0% 700 NA not evaluable AE (any grade)detailed results JAVELIN Bladder 100 (all population), 2020 13.83 [6.28; 30.48]
13.83 [6.28 ; 30.48 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 3.85 [2.72; 5.44]
3.85 [2.72 ; 5.44 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable AE leading to death (grade 5)detailed results JAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68]
4.03 [0.18 ; 89.68 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results JAVELIN Bladder 100 (all population), 2020 93.23 [5.71; 1522.42]
93.23 [5.71 ; 1522.42 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable SAE (any grade)detailed results JAVELIN Bladder 100 (all population), 2020 1.55 [1.09; 2.21]
1.55 [1.09 ; 2.21 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable STRAE (any grade)detailed results JAVELIN Bladder 100 (all population), 2020 68.24 [4.16; 1120.28]
68.24 [4.16 ; 1120.28 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable TRAE (any grade)detailed results JAVELIN Bladder 100 (all population), 2020 290.72 [105.09; 804.24]
290.72 [105.09 ; 804.24 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 133.97 [8.24; 2178.15]
133.97 [8.24 ; 2178.15 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable TRAE leading to death (grade 5)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable TRAE leading to discontinuation (any grade)detailed results JAVELIN Bladder 100 (all population), 2020 73.11 [4.46; 1198.64]
73.11 [4.46 ; 1198.64 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Arthritis TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Asthenia TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Chills TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Colitis TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68]
4.03 [0.18 ; 89.68 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Diabetes TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Dry skin TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Fatigue TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 20.63 [1.20; 354.60]
20.63 [1.20 ; 354.60 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 6.06 [0.30; 121.47]
6.06 [0.30 ; 121.47 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Myositis TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68]
4.03 [0.18 ; 89.68 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Nausea TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Nephritis TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Pruritus TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Rash TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Uveitis TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Anaemia AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.32 [0.57; 3.04]
1.32 [0.57 ; 3.04 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Arthralgia AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68]
4.03 [0.18 ; 89.68 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Asthenia AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 0.12 [0.01; 2.36]
0.12 [0.01 ; 2.36 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Back pain AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 0.50 [0.15; 1.66]
0.50 [0.15 ; 1.66 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Constipation AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68]
4.03 [0.18 ; 89.68 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Cough AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Decreased appetite AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 0.50 [0.05; 5.54]
0.50 [0.05 ; 5.54 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Diarrhoea AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.18; 22.29]
2.01 [0.18 ; 22.29 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Fatigue AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 3.04 [0.61; 15.19]
3.04 [0.61 ; 15.19 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Infusion-related reaction AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 6.06 [0.30; 121.47]
6.06 [0.30 ; 121.47 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Nausea AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 0.50 [0.05; 5.54]
0.50 [0.05 ; 5.54 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Pruritus AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Pyrexia AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Rash AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Vomiting AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.02 [0.37; 11.09]
2.02 [0.37 ; 11.09 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable 0.0 500.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 02:22 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 188
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563